Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study)

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 327-338

  Takeuchi, Tsutomu ^a   Tanaka, Yoshiya ^b   Kaneko, Yuko ^a   Tanaka, Eiichi ^c   Hirata, Shintaro ^b   Kurasawa, Takahiko ^d   Kubo, Satoshi ^b   Saito, Kazuyoshi ^b   Shidara, Kumi ^c   Kimura, Noriko ^a   Nagasawa, Hayato ^d   Kameda, Hideto ^a   Amano, Koichi ^d   Yamanaka, Hisashi ^c  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adalimumab; Japanese; Radiographic outcome; Retrospective study; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; METHOTREXATE; STEROID;

ADULT; ARTICLE; BLOOD DISEASE; CELLULITIS; CLINICAL PRACTICE; COLON DIVERTICULOSIS; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FIBULA FRACTURE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INJURY; INTERSTITIAL PNEUMONIA; INTOXICATION; JAPANESE; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MILIARY TUBERCULOSIS; MYCOBACTERIOSIS; NEOPLASM; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RADIOGRAPHY; RASH; REMISSION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865372548     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0516-6     Document Type: Article

References (32)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358: 903-11. (Pubitemid 32900579)
2. Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, et al. Mortality of rheumatoid arthritis in Japan: A longitudinal cohort study. Ann Rheum Dis. 2005;64:1451-5. (Pubitemid 41623856)
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-46.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370: 1861-74. (Pubitemid 350180008)
5. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16. (Pubitemid 32224400)
6. Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum. 1998;41(Suppl 9):S57.
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003;48:35-45. (Pubitemid 36091645)
8. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-16. (Pubitemid 38530193)
9. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400-11. (Pubitemid 38608061)
10. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumor necrosis factor-A monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30:2563-71. (Pubitemid 37549331)
11. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. (Pubitemid 43122183)
12. Miyasaka N, Takeuchi T, Eguchi K. Proposed [corrected] Japanese Guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15:4-8. (Pubitemid 40298416)
13. Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63-7.
14. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28-32. (Pubitemid 46455693)
15. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146-52.
16. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18:447-54.
17. Iwamoto N, Kawakami A, Fujikuwa K, Aramaki T, Kawashiri S, Tamai M, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488-92.
18. Miyasaka N, the CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: The CHANGE study. Mod Rheumatol. 2008;18:252-62.
19. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
20. Japan College of Rheumatology. Guidelines for adalimumab (in Japanese). 2008. http://www.ryumachi-jp.com/info/guideline-ADA.pdf
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
22. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45. (Pubitemid 10164318)
23. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-3. (Pubitemid 30058662)
24. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993;20:561-5. (Pubitemid 23102494)
25. Abbott Laboratories. Prescribing information for Humira(adalimumab). Chicago: Abbott Laboratories; 2010.
26. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644-52.
27. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A report from the registry of Japanese rheumatoid arthritis patients for long-term safety. J Rheumatol. 2011. doi: 10.3899/jrheum.101009.
28. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122-33.
29. Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.
30. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.
31. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol. 2009;36:907-13.
32. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:583-9.